Vogenx (NASDAQ:VOGX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Vogenx (NASDAQ:VOGX) to a hold rating in a research report report published on Saturday morning.

Vogenx Stock Performance

NASDAQ:VOGX opened at $30.73 on Friday. Vogenx has a one year low of $12.95 and a one year high of $35.00.

Vogenx Company Profile

Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.